# Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma

> **NCT05386056** · PHASE2 · UNKNOWN · sponsor: **Peking University** · enrollment: 54 (estimated)

## Conditions studied

- Esophageal Squamous Cell Carcinoma

## Interventions

- **DRUG:** Pembrolizumab
- **DRUG:** Sinoporphyrin Sodium
- **PROCEDURE:** Photodynamic therapy

## Key facts

- **NCT ID:** NCT05386056
- **Lead sponsor:** Peking University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-12-01
- **Primary completion:** 2023-10-31
- **Final completion:** 2024-06-30
- **Target enrollment:** 54 (ESTIMATED)
- **Last updated:** 2022-11-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05386056

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05386056, "Pembrolizumab and Photodynamic Therapy in Previously Treated Metastatic Esophageal Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05386056. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*